National Prescribing Trends and Cost Analysis of Antidepressants, Anxiolytics, and Hypnotics in England, 2010–2023
Human Psychopharmacology: Clinical and Experimental · 2025-09 · 40 (5)
DOI: 10.1002/hup.70011 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Psychopharmacology: Clinical and Experimental, online erschienen am 18.08.2025. Verfasst von Mike Stedman und 5 weiteren Autor:innen. Beteiligte Einrichtung: Res Consortium, Andover, UK. Hauptthemen laut MEDLINE: Antidepressive Agents, COVID-19, Anti-Anxiety Agents, Hypnotics and Sedatives. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
We describe prescribing of anxiolytics/hypnotics/antidepressants at an all‐England level between 2010 and 2023, taking account of the influence of the COVID‐19 pandemic‐period.
Methods
All Primary Care Prescribing data for England for anxiolytics/hypnotics/antidepressant agents taken as tablets or capsules from 1 January 2010 to 31 December 2023 were considered.
Results
Antidepressants: the greatest increases were in sertraline prescriptions increasing from 2.9million 2010 by 685% to 23.0 million‐2023; duloxetine increased by 545% to 3.9million prescriptions; mirtazapine by 269% to 12.4million prescriptions. Regarding cost, overall average cost fell 2010‐2023 by 54% from £4.86(Euros 5.68) to £2.25(Euros 2.63) per prescription. Anxiolytics: the number of prescriptions for anxiolytics fell 6.5–4.8 m (−27%) overall, with all anxiolytics falling except buspirone. The greatest period of fall was seen between 2018 and 2023. Lorazepam/diazepam/chlordiazepoxide were down 23%,16%, 88% respectively. Average cost of prescriptions fell by 13% to £3.20(Euros 3.74). Hypnotics: the number of prescriptions for hypnotics fell 41% from 9.8million to 5.8million in 2023. All prescriptions fell in number. Annual trends showed no deviations for the COVID‐19 core pandemic (2020/2021) years.
Conclusion
Overall trends demonstrate a more than doubling of antidepressant prescribing over the period 2010–2023, with similar volume reduction in anxiolytics/hypnotics over the same period. Such real world data facilitate the development of policy influencing insights for psychotropic prescribing management now and in coming years.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Res Consortium, Andover, UK.
- University of Manchester, Manchester, UK.
- Greater Manchester Mental Health, Manchester, UK.
- Institute of Psychiatry, London, UK.
- Department of Endocrinology, Salford Royal Hospital, Salford, UK.
ORCID-Profile: Adrian Heald
Zitieren
APA
Stedman, M., Davies, M., Levy, J. W., Ingram, J., Taylor, D., & Heald, A. (2025). National Prescribing Trends and Cost Analysis of Antidepressants, Anxiolytics, and Hypnotics in England, 2010–2023. Human Psychopharmacology: Clinical and Experimental, 40(5). https://doi.org/10.1002/hup.70011
Vancouver
Stedman M, Davies M, Levy JW, Ingram J, Taylor D, Heald A. National Prescribing Trends and Cost Analysis of Antidepressants, Anxiolytics, and Hypnotics in England, 2010–2023. Human Psychopharmacology: Clinical and Experimental. 2025;40(5). doi:10.1002/hup.70011
BibTeX
@article{Stedman2025,
author = {Stedman, Mike and Davies, Mark and Levy, John Warner- and Ingram, Joseph and Taylor, David and Heald, Adrian},
title = {National Prescribing Trends and Cost Analysis of Antidepressants, Anxiolytics, and Hypnotics in England, 2010–2023},
journal = {Human Psychopharmacology: Clinical and Experimental},
year = {2025},
volume = {40},
number = {5},
doi = {10.1002/hup.70011}
}
EUVIMED